The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Apr. 09, 2024

Filed:

Jul. 10, 2019
Applicant:

The Board of Trustees of the Leland Stanford Junior University, Stanford, CA (US);

Inventors:

Karen J. Parker, Stanford, CA (US);

Dean S. Carson, San Francisco, CA (US);

Antonio Y. Hardan, Stanford, CA (US);

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
A61K 38/095 (2019.01); A61K 9/00 (2006.01); A61K 38/09 (2006.01); G01N 33/74 (2006.01);
U.S. Cl.
CPC ...
A61K 38/095 (2019.01); A61K 9/0043 (2013.01); G01N 33/74 (2013.01); G01N 2333/575 (2013.01);
Abstract

Provided herein are methods for treating, reducing and/or ameliorating symptoms of autism spectrum disorder (ASD) in a subject, where at least one measure of social impairment, anxiety, or repetitive behaviors is treated and/or ameliorated. Aspects include intranasally administering arginine vasopressin (AVP), or an analog of vasopressin, to a subject (e.g., a child between 6 and 12 years of age and having endogenous pre-treatment levels between about 0.045 and about 4.028 pg/mL, where the mean was 1.324 pg/mL). In children having high pre-treatment blood levels of AVP (e.g., about 25% or more above the mean pre-treatment AVP blood levels of the treatment group; or having pre-treatment blood vasopressin levels greater than 1.324 pg/mL), the treatment was enhanced. Because no difference in pre-treatment blood AVP levels was observed between control and ASD subjects, it was surprising that AVP treatment was more effective in subjects having high pre-treatment AVP levels.


Find Patent Forward Citations

Loading…